Gadfly
Remicade Is a Litmus Test for PBMs
Decisions by CVS and Express Scripts have implications for pricing and perception.
This article is for subscribers only.
Biosimilars -- the equivalent of generic drugs for complicated and expensive medicines made by living cells -- are supposed to reduce prices and save the health care system billions of dollars by finally bringing competition to blockbuster drugs. But as Bloomberg News has chronicled, they've been slow to gain traction.
Groundwork for an acceleration may come as soon as September.